Canagliflozin (hemihydrate): High-Purity SGLT2 Inhibitor for Advanced Glucose Metabolism Research

Executive Summary: Canagliflozin (hemihydrate) is a small molecule SGLT2 inhibitor with ≥98% purity, validated by HPLC and NMR (APExBIO C6434). It specifically inhibits renal glucose reabsorption, with no evidence for mTOR inhibition in yeast models (Breen et al., 2025). The compound is insoluble in water but highly soluble in DMSO and ethanol, making it suitable for diverse in vitro and in vivo protocols. Its mechanism and selectivity make it a preferred tool for research into glucose homeostasis and diabetes. Misapplication as an mTOR pathway inhibitor is unsupported by current evidence.

Biological Rationale

Canagliflozin (hemihydrate), also known as JNJ 28431754 hemihydrate, is designed to inhibit sodium-glucose co-transporter 2 (SGLT2), a protein expressed predominantly in the renal proximal tubule. SGLT2 is responsible for approximately 90% of glucose reabsorption in the kidney. Inhibition of SGLT2 promotes urinary glucose excretion, directly lowering blood glucose levels. This mechanism positions Canagliflozin (hemihydrate) as a central research tool in the study of glucose homeostasis and diabetes mellitus (APExBIO). High-purity SGLT2 inhibitors allow for reproducible, mechanistic investigations that inform metabolic disorder research (see related analysis; this article provides updated specificity data not covered in the linked review).

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) selectively inhibits SGLT2 by binding to its glucose transport site, blocking renal glucose reabsorption. The compound is a small molecule with the chemical formula C₂₄H₂₆FO_5.5S and a molecular weight of 453.52 g/mol. Upon administration in research models, it increases urinary glucose excretion, reducing plasma glucose concentrations. Its specificity for SGLT2 over SGLT1 and lack of direct activity on other metabolic kinases, including mTOR, have been confirmed in both in vitro and cell-based assays (APExBIO; Breen et al., 2025). The compound is not a substrate for common drug efflux pumps in standard mammalian models, supporting its use in metabolic disorder pathways research. For a systems biology perspective on its mechanistic selectivity, see (detailed comparison here; this article clarifies mechanistic boundaries beyond the systems biology overview).

Evidence & Benchmarks

• Canagliflozin (hemihydrate) inhibits SGLT2-mediated glucose reabsorption without affecting mTOR/TOR pathways in yeast or mammalian systems (Breen et al., 2025).
• The compound exhibits ≥98% purity (HPLC, NMR), supporting reproducible results in cell-based and biochemical assays (APExBIO).
• Solubility parameters: insoluble in water; DMSO ≥83.4 mg/mL; ethanol ≥40.2 mg/mL at room temperature (APExBIO).
• Recommended storage at -20°C; short-term shipping on blue ice preserves compound stability and activity (APExBIO).
• No TOR pathway inhibition was observed in drug-sensitized yeast models at concentrations up to 100 μM, in contrast to known TOR inhibitors (e.g., Torin1, rapamycin) that show robust effects at nanomolar levels (Breen et al., 2025).

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) is widely used in glucose metabolism, diabetes mellitus, and renal physiology research. Applications include:

• Probing glucose homeostasis pathways in cultured cells, organoids, and in vivo models.
• Benchmarks for SGLT2 inhibitor selectivity in mechanistic and pharmacodynamic studies.
• Comparative analysis with other metabolic modulators, including mTOR inhibitors, to clarify pathway specificity (extended specificity analysis; this article updates and summarizes negative data in mTOR inhibition not previously highlighted).

Common Pitfalls or Misconceptions

• Misapplied as an mTOR inhibitor: No TOR pathway inhibition was detected in yeast or mammalian assays up to 100 μM (Breen et al., 2025).
• Long-term solution storage: Solutions degrade; use freshly prepared stocks for experimental consistency (APExBIO).
• Inappropriate solvent use: Water is unsuitable for dissolution; use DMSO or ethanol to achieve desired concentrations.
• Diagnostic or therapeutic misuse: Product is strictly for research use; not approved for clinical or diagnostic applications.
• Confusion with SGLT1 inhibition: Canagliflozin (hemihydrate) shows higher selectivity for SGLT2 over SGLT1, with minimal off-target activity.

Workflow Integration & Parameters

For optimal results, dissolve Canagliflozin (hemihydrate) in DMSO (≥83.4 mg/mL) or ethanol (≥40.2 mg/mL) at room temperature. Avoid water-based solvents due to insolubility. Prepare solutions fresh before use, as prolonged storage reduces potency. Store dry powder at -20°C and ship on blue ice when possible. Typical concentrations in cell-based assays range from 0.1 μM to 100 μM, depending on experimental design and model system (APExBIO). For advanced protocol guidance, consult recent scenario-driven recommendations (see optimized protocols here; this article offers specific guidance for cytotoxicity and viability assays not included in prior overviews).

Conclusion & Outlook

Canagliflozin (hemihydrate) from APExBIO (C6434) is a robust, high-purity SGLT2 inhibitor that enables precise investigation of glucose metabolism and diabetes mellitus pathways. It demonstrates strong selectivity for SGLT2 and lacks mTOR/TOR inhibitory activity, distinguishing its experimental utility from rapalogs and other metabolic modulators. Future research may explore combinatorial approaches using SGLT2 inhibitors in tandem with other pathway modulators to further dissect the molecular underpinnings of metabolic disorders. This dossier clarifies mechanistic boundaries and provides actionable benchmarks for informed reagent selection. For complete product specifications and ordering, visit the Canagliflozin (hemihydrate) product page.